在骨髓中，myHSCs和淋巴系造血干细胞（lyHSCs）的数量对比进一步显示了Sema4A缺失对髓系细胞的过度偏向（g、h）。特别是髓系前体细胞（MyPro）和红系前体细胞（CFU-E）的数量变化，也支持了Sema4A缺失与髓系扩展的关系。

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

AML 作为一种侵袭性血液恶性肿瘤，具有显著的生物学和临床异质性，精准的风险分层对优化治疗效果、减少治疗相关并发症至关重要。目前，细胞遗传学变化和基因突变已被用于风险分层，其中 NPM1 和 FLT3-ITD 是 AML 患者中最常见的复发性基因突变 。然而，对这些突变进行分子检测存在诸多挑战，如不同机构资源和实验室基础设施差异大，限制了检测的可及性，延长了检测周转时间。

Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

In a paper published in Science Bulletin, a Chinese team of scientists reported a comprehensive proteogenomic analysis of 101 Chinese AML patients, including proteomic and phosphoproteomic analyses ...

Myeloid lineage cells, including macrophages, dendritic cells, osteoclasts and precursor cells, all produce VEGF-C in response to inflammatory cytokines, which is mediated by the canonical NF-κB ...

This valuable study presents a mouse gastruloid model that can be used to generate hematopoietic progenitors as well as leukemic cells. However, in its current form, the manuscript is inadequate ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

These data are consistent with previous GPS trials. In the Phase 2 study in AML patients in second complete remission, the median overall survival of GPS-treated patients was 21 months versus 5.4 ...